Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by hmmmmmmmmon Dec 08, 2021 3:10pm
110 Views
Post# 34211674

RE:RE:RE:Under promise and

RE:RE:RE:Under promise and I have a record of calling out management harshly- for not delivering on enrollment numbers and for not being transparent.

They cleared up a lot of the transparency issues for me on the 10/30 conference call. I did not see the hedge on any questions, in fact I heard them address tough questions that weren't asked but were raised on this bullboard.

Their answers were logical and it buys them time with me to show enrollment results and deliver.

I also belive there is a big near term catalyst- when they announce DaVita as a DIMI trial partner and that announcement will have to happen before that trial starts- so Q1.

If solid enrollment and a partnership with Toray, Baxter and DaVita doesn't start to turn the SP tide... well, up is down- and I imagine it will be a more frustrating ride until we get closer to final trial results. 
<< Previous
Bullboard Posts
Next >>